Loading
LILRB1 is a brake on macrophages, dendritic cells and some NK and T cells that reads ordinary HLA class I, so any cell showing HLA is protected. Antibodies that block it, with or without LILRB2, are in early trials. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
An ITIM-bearing LILR; LILRB receptors negatively regulate myeloid maturation and permit a suppressive myeloid phenotype in tumours (van der Touw et al. 2017).
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"LILRB1" OR ABSTRACT:"LILRB1" OR TITLE:"ILT2" OR ABSTRACT:"ILT2" OR TITLE:"LIR-1" OR ABSTRACT:"LIR-1" OR TITLE:"CD85j" OR ABSTRACT:"CD85j" OR TITLE:"leukocyte immunoglobulin like receptor B1" OR ABSTRACT:"leukocyte immunoglobulin like receptor B1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LILRB1 (ILT2), not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/lilrb1.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/lilrb1.json. Licence CC BY-NC 4.0.